KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Deffered Revenue (2017 - 2023)

BeOne Medicines (ONC) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $300000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Non-Current Deffered Revenue fell 99.29% to $300000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $300000.0, a 99.29% decrease, with the full-year FY2023 number at $300000.0, down 99.29% from a year prior.
  • Non-Current Deffered Revenue was $300000.0 for Q4 2023 at BeOne Medicines, roughly flat from $300000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $220.3 million in Q4 2021 to a low of $300000.0 in Q3 2023.
  • A 4-year average of $81.6 million and a median of $52.3 million in 2021 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 186.77% in 2022, then tumbled 99.8% in 2023.
  • BeOne Medicines' Non-Current Deffered Revenue stood at $8.2 million in 2019, then skyrocketed by 2573.41% to $220.3 million in 2021, then plummeted by 80.92% to $42.0 million in 2022, then crashed by 99.29% to $300000.0 in 2023.
  • Per Business Quant, the three most recent readings for ONC's Non-Current Deffered Revenue are $300000.0 (Q4 2023), $300000.0 (Q3 2023), and $24.3 million (Q2 2023).